Drug intelligence / Profile preview

ASP2074

Development stage: Discontinued
Lead developer: Astellas Pharma Global Development, Inc.
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ASP2074 is an investigational bispecific antibody developed for the treatment of solid tumors. Its mechanism of action involves dual targeting as a Tetraspanin 8 inhibitor and a CD3 antigen inhibitor, aiming to engage the immune system against cancer cells by redirecting T cells to tumor cells expressing TSPAN8. The drug is administered intravenously and has been studied in adults with metastatic or locally advanced solid tumors who have exhausted standard therapies. Development was led by Astellas Pharma[2][5][7].

Targets

TSPAN8 (Tetraspanin-8)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on ASP2074.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP2074.

Explore the full profile